Manuel Hidalgo Medina
Scientific AdvisorDr. Manuel Hidalgo Medina M.D., Ph.D., is Director & Member of Advisory Council of American Association For Cancer Research. Dr. Manuel Hidalgo Medina serves as Member of Advisory Board at Eckuity LLC. He serves as Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine/NewYork-Presbyterian Hospital since 2019. At Weill Cornell Medicine, he also serves as the E. Hugh Luckey Professor of Medicine and Associate Director for Clinical Services at the Sandra and Edward Meyer Cancer Center. Dr. Hidalgo serves on the Board of Bristol-Myers Squibb Company since 2021 and as Director at the American Association for Cancer Research from 2024. He serves as a Member of the Scientific Advisory Board at MiNK Therapeutics, Inc., Thetis Pharmaceuticals LLC, Nectin Therapeutics Ltd., VCN Biosciences SL, Oncomatryx Biopharma, S.A. and KAHR Medical Ltd. He serves as Scientific and Clinical Advisor for Vesselon Inc. and Scientific Advisor for Champions Oncology, Inc. and as a Member of the Scientific Board of Targeted Molecular Diagnostics LLC. He also serves as a Member of the OncoAssist Advisory Board at MedTrust Online, LLC and as Director of Centro Integral Oncologia “Clara Campal” in Madrid, Spain. He is Co-founder and Chairman of the International Pancreatic Cancer Research Team and a Member of the NCI Developmental Therapeutics Study. He has also served as a European Strategy Consultant. Previously, he served as a Member of Medical & Scientific Advisory Board at PharmaCyte Biotech, Inc. from August 2022 until 2023 and as its Chair of Medical and Scientific Advisory Board until August 2022. He served as a Member of Scientific Advisory Board at Agenus Inc. until November 2021. From 2015 to 2019, he served as Chief of the Division of Hematology at Beth Israel Deaconess Medical Center and Clinical Director of the Rosenberg Clinical Cancer Center and as the Theodore W. and Evelyn G. Berenson Professor of Medicine at Harvard Medical School. He served as an Advisor of Cavion LLC until August 2017. He served as Director of Champions Biotechnology Inc. from June 11, 2007 to April 2008 and as its Chief Scientific Officer beginning in March 2008 and also served as its Scientific Advisor. He served as a Member of the Scientific Advisory Board of Aclara Biosciences Inc. since October 2004, as well as a Member of Scientific Advisory Board at Panbela Therapeutics Inc. and Monogram Biosciences Inc. Dr. Hidalgo held senior leadership roles at the Spanish National Cancer Research Centre (CNIO), where he served as Director of Oncology. He also served as Director of the Gastrointestinal Oncology Program at the Sidney Kimmel Comprehensive Cancer Center and as Associate Professor of Oncology and Co-Director of the Drug Development Program at Johns Hopkins University School of Medicine. He worked as an Assistant Professor of Medicine at the University of Texas Health Science Center and as a clinical investigator at the Cancer Therapy and Research Center, where he began his career in 1997 as a clinical research fellow, participating in the EORTC/NCI Exchange Fellowship and AACR Young Investigator Fellowship in Clinical Research. He trained and later served on faculty at MD Anderson Cancer Center. Dr. Hidalgo is widely regarded as one of Europe’s leading clinical and laboratory investigators in pancreatic cancer and a leading researcher in the development of targeted therapies for solid tumors. He has participated in the clinical development of more than 30 novel anticancer agents and led early clinical trials involving erlotinib and temsirolimus. He pioneered the use of personalized xenograft models for drug screening, biomarker development and personalized cancer treatment. His research focuses on optimizing clinical development of novel therapies through analysis of molecular targets, tumor biology and therapeutic response in patients. His clinical trials group focuses on novel therapeutics for pancreatic cancer and he has served as Principal Investigator on multiple clinical studies in drug development programs. He has published more than 220 peer-reviewed papers and authored a New England Journal of Medicine review on pancreatic cancer treatment. His research has been funded by numerous organizations including the National Cancer Institute (NCI), National Institutes of Health (NIH), American Association for Cancer Research (AACR) and American Society of Clinical Oncology (ASCO). He received the ASCO Career Development Award in 2001 and an AACR Clinical Research Fellowship. Dr. Hidalgo serves on the Editorial Boards of the Journal of Clinical Oncology and Clinical Cancer Research and is Senior Editor for Molecular Cancer Therapeutics. He specialized in Medical Oncology at the University Hospital “12 de Octubre” in Madrid in 1996 and completed training in drug development at the University of Texas Health Science Center, San Antonio. He received his Medical Degree from University Navarra Medical School and his Ph.D. in Infectious Diseases in Cancer from University Autónoma in Madrid. Dr. Medina is Director of Guardant Health, Inc. from July 18, 2024.
公司职务
- 公司名称Champions Oncology, Inc.股票代码CSBR职务Scientific Advisor
